OBJECTIVE-Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents suggests a protective effect of GLP-1 on brain tissue. The mechanism is unknown. We therefore tested whether these neuroprotective effects could relate to changes of glucose transport and consumption.
G
lucagon-like peptide-1 (GLP-1) is an incretin hormone with several beneficial effects on glucose homeostasis. GLP-1 is not solely produced by the entero-endocrine L-cells in the gut but also in the brain by neurons in the nucleus of the tractus solitarius and thus functions as a neuropeptide (1) . It stimulates insulin secretion and inhibits glucagon secretion in the presence of glucose, inhibits gastric emptying, and reduces appetite and food intake (2, 3) . Furthermore, it acts as a ␤-cell growth factor by stimulating ␤-cell proliferation and islet neogenesis and by reducing ␤-cell apoptosis (4) . The glucose dependency of GLP-1 action on insulin and glucagon secretion results in a low risk of hypoglycemic episodes (5) . These effects make GLP-1 attractive as an anti-diabetes medication, and several studies prove the beneficial effect on glucose homeostasis in the type 2 diabetic patient (6, 7) .
Although GLP-1 receptors (GLP-1Rs) are predominantly located on the ␤-, ␦-, and presumably ␣-cells of the pancreas, receptors in other tissues may mediate GLP-1's effects outside the pancreas (8, 9) , where gastric emptying and appetite are well-known targets, as are other tissues including heart, kidney, and lungs (8) . GLP-1R expression has been demonstrated in human brain (10) , where receptors are particularly abundant in the paraventricular nucleus and the arcuate nucleus in the hypothalamus (11) . Infusion of GLP-1 dose-dependently enhances satiety and reduces food intake in normal and obese subjects, including those with type 2 diabetes, and neural mechanisms appear to be involved (3) .
The abundance of receptors in other locations in the brain, i.e., the thalamus, brainstem, lateral septum, subfornical organ, area postrema, the cerebral cortex, cerebellum, and caudate-putamen, as well as in the hippocampus, suggests that GLP-1 may have additional effects in the central nervous system as a whole (10, 12) . This is also evident from GLP-1R-knock-out mice, who have seriously disturbed learning abilities (13) .
Recent studies in rodents provide evidence of both neuroprotective and neurotrophic effects of GLP-1 (13, 14) , including improvement of learning and memory (13) . The mechanism of these putative protective effects of GLP-1 in the central nervous system is unknown. Applied directly to the rodent brain, GLP-1 affects peripheral glucose metabolism (15) , implying that interaction exists among GLP-1, brain, and glucose homeostasis.
In the brain, intracellular and interstitial glucose concentrations are maintained by the stereospecific and nonenergy-demanding mechanism of facilitated diffusion, mediated by the GLUT1 transporter, across the bloodbrain barrier (BBB). BBB glucose transfer is downregulated during hyperglycemia (16, 17) and stimulated during hypoglycemia (18) . As insulin has no measurable effect on blood-brain glucose transfer (19, 20) , it remains uncertain how the non-insulin-dependent glucose transport across the BBB is regulated. GLP-1 itself has been shown to cross the BBB by passive diffusion (21) .
Because the role of glucose delivery and metabolism in neuroprotection is unclear, we tested the hypothesis that an interaction exists between GLP-1 and delivery of glucose by measuring the transport and metabolism of the glucose tracer 18-fluoro-deoxy-glucose (FDG) during positron emission tomography (PET) under the influence of GLP-1.
RESEARCH DESIGN AND METHODS
Eleven nonsmoking, healthy, Caucasian, male subjects were included in the study; one subject was withdrawn due to uncompleted PET scan. Mean (Ϯ SD) age was 25 Ϯ 3 years, and BMI was 22.6 Ϯ 0.6 kg/m 2 . They had no history of diabetes or cardiovascular disease and received no medication. All had a normal physical examination. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the local ethics committee of the County of Aarhus. All participants received both oral and written information and signed an approved informed consent form before entering the study.
The study was carried out as a randomized, double-blinded, placebocontrolled cross-over study. Each subject was studied twice in random order with GLP-1 and placebo infusion. PET sessions were separated by an interval of 4 -6 weeks. Both sessions commenced at 0800 h after an overnight fast, and subjects did not exercise 24 h before the sessions. Subjects were placed in bed, and two catheters were inserted for infusion of clamp hormones and for the infusion of GLP-1 or placebo. A third catheter was placed in an arterialized (heated) dorsal hand vein for blood sampling.
The randomization was performed by the pharmacy at Aarhus University Hospital, and the randomization list was kept at the pharmacy during the study. Sealed envelopes containing information about the code were delivered together with the study medication at day 1 and kept unbroken in the case report form. The code was broken after all data analysis was completed.
A pancreatic-pituitary clamp was performed according to principles previously described (22) . In brief, somatostatin (D-24109 Kiel; Ferring) was infused at a rate of 300 g/h to suppress endogenous insulin, glucagon, growth hormone, and GLP-1 production. Human glucagon (0.6 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) (Glucagen; Novo Nordisk, Copenhagen, Denmark), growth hormone (2 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) (Genotropin Miniquik, 0.2 mg; Pfizer, Ballerup, Denmark), and insulin (0.12 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 ) (Actrapid; Novo Nordisk) were infused with the aim of maintaining near-basal levels (0 -360 min). Glucose (200 g/l) was infused at a variable rate to clamp plasma glucose close to 4.5 mmol/l. Euglycemia was maintained in order to assess a physiological role of GLP-1 at the BBB independent of insulin and glucagon levels and independent of a direct effect of plasma glucose on GLP-1 action.
The subjects received either intravenous recombinant GLP-1 (rGLP-1)(7-36 amide) or placebo at a rate of 1.2 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 (60 -360 min) (23). rGLP-1(7-36 amide) was tested and found positive for sterility and negative for bacterial endotoxins. It was dissolved in a sterile buffer containing 600 mg acetoacid, 50.7 g mannitol, and sterile water added up to 1,000 g and had a pH of 4.5. The concentration of rGLP-1(7-36) was 1 mg/ml and stored frozen in vials of 0.25 ml. The test solution consisted of 0.25 ml rGLP-1 (1 mg/ml), 20 ml human albumin ZLB 5%, and NaCl (9 g/l) up to 100 ml of solution. The placebo solution consisted of the above-mentioned buffer solution containing human albumin and NaCl.
Plasma glucose was measured in duplicate every 10 min. Blood for measuring insulin, C-peptide, glucagon, GLP-1 (total and intact), growth hormone, free fatty acids, cortisol, and ghrelin was drawn every 30 min. Blood for measuring epinephrine and norepinephrine was drawn at 0, 150, and 240 min and every 30 min during the PET scan. Assays. Plasma glucose was measured immediately after sampling on a Beckman glucose analyzer (Beckman, Palo Alto, CA). All other blood samples were stored at Ϫ20°C (C-peptide at Ϫ80°C) until assay.
The assays used for measuring serum insulin, serum C-peptide, serum free fatty acid, serum growth hormone, serum cortisol, plasma epinephrine, and plasma norepinephrine are described previously (24) . S-ghrelin was measured with an in-house assay (25) .
The assay for intact GLP-1 is an enzyme-linked immunosorbent assay using unextracted plasma, which was collected and stored in the presence of a dipeptidyl peptidase-IV inhibitor (valine-pyrrolidide, 0.01 mmol/l, final concentration added to the blood sample immediately after collection). Total GLP-1 was analyzed using a C-terminal radioimmunoassay for amidated GLP-1 (26) . Glucagon was measured using a previously described assay (27) . PET. FDG was used as a tracer for brain glucose uptake and was produced in house according to Drug Master File, Danish national marketing authorization number 2165. We used a whole-body PET model EXACT HR47 (Siemens Medical, Knoxville, TN) with a 15-cm field of view and an acquisition capacity of 47 transaxial planes with a spatial resolution of 4 -5 mm at the center of the field of view. All PET data were acquired in three-dimensional mode.
A 15-min transmission scan was performed to correct photon attenuation. Five hours after clamp start and 4 h after the GLP-1 or placebo infusion was started, a bolus of 200 MBq of FDG in 10 ml saline was injected intravenously over 10 s. Dynamic acquisition commenced at the beginning of tracer injection and continued for 45 min to acquire 23 frames (6 ϫ 30 s and 7 ϫ 1, 5 ϫ 2, and 5 ϫ 5 min).
For the extraction of region-specific PET data results, regions of interest were automatically extracted using a model-based segmentation approach (28) based solely on the registration of PET images to a standardized anatomic atlas. Regional tissue time-activity curves for FDG uptake were extracted for total cerebral gray matter, cerebral cortex, thalamus, striatum, cerebellar cortex, brainstem, and white matter.
Image-derived arterial input functions were automatically obtained by localizing the carotic artery on the PET images for each subject from each study day. An automated method for identification of the most probable voxel positions for the arteries was developed. Using a three-compartment model, we obtained values of unidirectional clearance (K 1 *), efflux coefficient (k 2 *), and phosphorylation rate constant (k 3 *) for FDG in each region of interest. The rate of dephosphorylation and the absolute quantity of FDG were both considered negligible during the scanning period and are therefore not part of the model. The lumped constant is the conversion factor between the net uptakes of FDG and glucose as functions of transport across the BBB and the phosphorylation. In the model of competition between native glucose and FDG in brain, both transport across the BBB (K 1 *, k 2 *), and phosphorylation by hexokinase (k 3 *) can be described by the Michaelis-Menten equation. This permits the use of fixed transport ( ϭ K 1 */K 1 ) and phosphorylation ( ϭ k 3 */k 3 ) rate ratios for tracer and native glucose. (Those marked with * indicate FDG.)
By substituting transfer constants of FDG for those of glucose, using and , the lumped constant was determined directly for each subject in each region of interest as described previously (29) . In this study we used the value of ϭ 1.48 and ϭ 0.39 (30) .
The net clearance of FDG was calculated as:
The unidirectional glucose transfer was calculated as:
where J glc is the unidirectional transport of glucose from blood to brain (influx of glucose), Ca equals the arterial steady-state plasma glucose concentration (300 -360 min), and (as above) those marked with * indicate FDG. The lumped constant (LC) was calculated as:
The net clearance of glucose was calculated as:
The cerebral metabolic rate of glucose (CMR glc ) was calculated as:
And the cerebral tissue glucose concentration C t was calculated as:
ϫ (Jglc -CMRglc)/k2* Calculations and statistics. Primary end points were transfer coefficients of BBB glucose transport and unidirectional glucose transfer across the BBB at normal glycemia. Secondary end points were cerebral metabolic rate for glucose, cerebral tissue glucose concentration, and lumped constant. The PET data were analyzed using a linear mixed-effects model with subject and all interactions involving subject, i.e., the interaction between subject and area and the interaction between subject and treatment, as random effects. Treatment (GLP-1/placebo), region, and the interaction between the two were included in the analysis as fixed effects. Data were transformed when appropriate based on an inspection of the residuals, and results are therefore presented as back-transformed estimated means with 95% CIs. The statistical software used was PROC MIXED in SAS (SAS Institute, Cary, NC) with a significance level of 5%. To compare the two treatment groups regarding circulating hormones and metabolites, a similar statistical model was used with time instead of region. Data are presented as means Ϯ SEM.
RESULTS
The infusion of GLP-1 at a constant rate of 1.2 pmol ⅐ kg
Ϫ1
⅐ min Ϫ1 resulted in pharmacologically relevant plasma concentrations of the intact hormone (31) (Fig. 1) .
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During PET, the plasma glucose concentration was successfully maintained at 4.6 Ϯ 0.04 (GLP-1) and 4.6 Ϯ 0.03 (placebo) mmol/l (P ϭ 0.74) with similar glucose infusion rates (1.81 Ϯ 0.30 vs. 1.55 Ϯ 0.32 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 for GLP1 vs. placebo, P ϭ 0.22) (Fig. 2) . The plasma C-peptide level was suppressed (P ϭ 0.66). As expected, there were no significant differences in circulating hormones and metabolites between sessions. Insulin, glucagons, and growth hormone infusions resulted in low, close to basal levels of these hormones (P Ͼ 0.24) (Fig. 3) . Ghrelin, norepinephrine, cortisol (data not shown), and epinephrine levels were also low and did not change between sessions (P Ͼ 0.14). Only plasma GLP-1 levels differed between sessions (P Ͻ 0.001).
There was an overall significant effect of GLP-1 on the unidirectional clearance of glucose (K 1glc ), but it was not the same in all regions (P ϭ 0.015 for the interaction between region and treatment) ( Table 1) . K 1glc was decreased by 20 -27% (P ϭ 0.02-0.08) in the seven brain regions; the efflux coefficient for FDG (k 2 *, data not shown) was decreased by 26 -39% (P ϭ 0.03) with GLP-1 infusion compared with placebo.
No significant change in the phosphorylation coefficient for FDG (k 3 *, data not shown) was observed (P ϭ 0.39), and the net clearance of FDG (K*, data not shown) (P ϭ 0.58) and of glucose (K glc ) (P ϭ 0.25) was unchanged with GLP-1 infusion. A tendency toward increased lumped constant with GLP-1 infusion was seen in all regions (P ϭ 0.08). The unidirectional glucose transfer (J glc ) across the BBB was reduced by GLP-1 infusion in all brain regions but not by the same amount (P ϭ 0.01 for the interaction between region and treatment) (Fig. 4A) . In specific brain regions, J glc was reduced by 23-30% (P ϭ 0.02-0.06) with GLP-1 infusion. The cerebral metabolic rate for glucose (CMR glc ) was reduced by 12-18% with GLP-1 infusion, but the difference was not significant (P ϭ 0.28) (Fig. 4B) . The brain tissue glucose concentration remained the same in all regions with and without GLP-1 infusion (P ϭ 0.89) (Fig. 4C) . Two subjects experienced transient nausea starting after ϳ1 and 3 h and with a duration of 5 and 1 h, respectively.
DISCUSSION
In general, the search for a regulatory mechanism of BBB glucose transfer operating in the brain vasculature has failed (32) . The only known factor affecting BBB glucose transfer therefore remains the plasma glucose level itself. In vitro, animal studies have shown that GLP-1 signaling is involved in neuronal plasticity and neuroprotection (13), and GLP-1R activation has effects in the nervous system comparable with those of nerve growth factor (14) . No human studies have linked GLP-1, cerebral glucose transport, and neuroprotection. Yet, maintaining a constant glucose concentration in brain tissue is important to the preservation of neuronal functioning. Several studies have shown characteristic electroencephalogram changes during hypoglycemia (plasma glucose Ͻ2.0 mmol/l) in both type 1 diabetic and healthy subjects (33, 34) . Hyperglycemia with concomitantly increased glucose concentration in brain tissue accelerates ischemic damage and worsens the outcome after ischemic stroke (35) . Although, physiologically, the BBB glucose clearance is lower in acute hyperglycaemia, the absolute flux is of course elevated (17) , and it still remains unclear whether the reduction of plasma glucose during stroke is neuroprotective, as trials are ongoing (36) .
To our knowledge, the current study for the first time reveals that GLP-1 potentially regulates BBB glucose transfer. Independently of the insulin and glucagon levels, GLP-1 reduces unidirectional glucose delivery across the intact BBB at normoglycaemia. The cerebral glucose metabolism tended also to decline, but the tissue glucose concentration remained constant. Together the data implies that GLP-1 maintains a constant glucose concentration in the brain at normal glycaemia by limiting the glucose delivery across the BBB. We anticipate that if the effect is due to a decline of the maximal transport (T max ), it would be even more pronounced during hyperglycaemia.
However, the cerebral glucose metabolism does not depend strongly on the glucose concentration in the brain intracellular and interstitial fluids because brain hexokinase is saturated at the prevailing glucose concentration. Since the tissue glucose concentration depends on the glucose phosphorylation rate, the BBB transfer assumes a very important role in the maintenance of glucose concentration in the brain (37) . In the brain, the unidirectional glucose transport rate increases concurrently with increasing glycemia. Because the transport is only half saturated at ϳ4 mmol/l (38), the fraction of glucose that passes from blood to brain continues to decrease with increasing glycemia.
The net clearance of FDG (K*) in the current study was 4.4 ml/100 cm 3 per min (95% CI 3.5-5.6), which is comparable to values found in the literature (4.2 ml ⅐ 100 g Ϫ1 ⅐ min Ϫ1 ) (1 g brain tissue approximates a volume of 1 cm 3 ). However, in the current study, the unidirectional glucose transport in total cerebral gray matter was 93 mol/100 cm 3 per min (range 77-114), which is approximately twice as high as previously reported values for whole brain, mostly explained by the focus on gray matter in the present study and the still imperfect methods of computing whole-brain glucose transport rates from regional values with PET. Values of the lumped constant for humans ranges from 0.50 to 0.80, and in the present study we obtained a lumped constant for gray matter of 0.55 (range 0.52-0.58) (30) . The cerebral metabolic rate for glucose we obtained in total cerebral gray matter was 37 mol/100 cm 3 per min (range 30 -46), which is somewhat higher than the whole brain value of 25-30 mol ⅐ 100 g Ϫ1 ⅐ min Ϫ1 (39) . Cerebral blood flow was not measured in this study; however, clearance (K) in principle is a measure that includes any blood flow effect, as it is the product of an extraction fraction (unidirectional or net extraction) and the plasma flow. Therefore, any blood flow effect is included in the clearance, which in turn is the measure that describes the flux when multiplied with the concentration. This description does not of course exclude the possibility that the change in clearance is the result of a blood flow change, but the effect is the effect measured as the clearance.
The effect of GLP-1 on the unidirectional clearance of glucose was not the same in all regions. But indeed a trend was observed in all regions, indicating that the effect is potentially uniformly seen in all brain regions with an intact BBB. In the brain, facilitated glucose diffusion across the BBB maintains a glucose concentration in brain tissue that is lower than in plasma and similar to that in cerebrospinal fluid (40) . Calculated levels in the present brain regions are consistent with the highest levels in the most active part of gray matter and the lowest levels in white matter.
Individual lumped constants were calculated for each brain region. The lumped constant tended to increase during GLP-1 infusion in all brain regions. Because of the Michaelis-Menten kinetic competition for blood-brain transfer of glucose and glucose analogues, the lumped constant is in fact a variable that depends on the plasma glucose concentration and the relation between brain and plasma glucose.
In a single FDG-PET study, GLP-1 receptor activation reduced glucose metabolism in areas of the hypothalamus and brainstem involved in feeding and glucose sensing, where receptors are abundant (41) . However, it was not apparent whether the effect was due to reduced glucose transport across the BBB and/or reduced phosphorylation 
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of glucose by hexokinase. No effect was observed in other brain areas. Caveats of the study noted are that circulating levels of glucose, insulin, and glucagon were uncontrolled during and after the short (30 min) GLP-1 exposure and that PET commenced 10 min after the end of GLP-1 infusion. As the half-life of GLP-1 is Ͻ2 min due to enzymatic degradation by ubiquitously represented dipeptidyl peptidase-IV (42), the true plasma GLP-1 concentrations are uncertain, and it is unknown whether pharmacologically relevant levels were reached during the PET examination.
In the present study, we demonstrate that GLP-1 reduces BBB transport of glucose in general in the brain. The interaction of GLP-1 with the normal human BBB is therefore a novel finding. The glucose transport across the BBB is mediated by the transporter GLUT1. We speculate that GLP-1 interacts with the GLUT1 transporter and the GLP-1 receptor in the BBB.
GLP-1 has a role in the maintenance of cerebral glucose balance and may have neuroprotective effects linked to both peripheral and cerebral glucose metabolism. During hyperglycemia, GLP-1 is secreted from the gut into the blood stream and may also be produced in the brain, as central GLP-1 signaling appears to be linked to the control of blood glucose concentrations (15, 43) . GLP-1 efficiently promotes disposal of glucose, and circulating glucose is reduced by means of increased insulin secretion and decreased glucagon secretion, thereby limiting glucose transport across the BBB. Here, we show that GLP-1 has an important effect that could be independent of insulin action. Hence, both peripheral and central actions of GLP-1 efficiently limit glucose fluctuations in the brain that may be of neuroprotective significance. Thus, under conditions with pharmacologically elevated levels of GLP-1, we propose a new extrapancreatic effect of GLP-1 in the brain that provides a link between brain glucose transport and neuroprotection.
